Table 2.
Medications use at discharge and follow-up.
| Medications | Control group (n=72) | Intervention group (n=80) |
|---|---|---|
| At discharge | ||
| ACEi/ARB, n (%) | 58 (80.6) | 65 (81.3) |
| Beta-blocker, n (%) | 52 (72.2) | 58 (72.5) |
| Loop diuretic, n (%) | 72 (100) | 80 (100) |
| Aldosterone receptor antagonist, n (%) | 46 (63.9) | 49 (61.3) |
| Antiplatelet, n (%) | 50 (69.4) | 55 (68.7) |
| Statins, n (%) | 50 (69.4) | 58 (72.5) |
| Antidiabetic, n (%) | 40 (55.6) | 44 (55) |
| At 12-week follow-up | ||
| ACEi/ARB, n (%) | 43 (59.7) | 59 (73.8)* |
| Beta-blocker, n (%) | 37 (51.4) | 50 (62.5)* |
| Loop diuretic, n (%) | 67 (93.1) | 74 (92.5) |
| Aldosterone receptor antagonist, n (%) | 39 (54.2) | 48 (60)* |
| Antiplatelet, n (%) | 49 (68.1) | 53 (66.3) |
| Statins, n (%) | 50 (69.4) | 55 (68.9) |
| Antidiabetic, n (%) | 36 (50) | 41 (51.3) |
ACEi/ARB – angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; P<0.05 versus control group.